Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
10
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 22 publications
(11 citation statements)
references
References 121 publications
1
10
0
Order By: Relevance
“…Upregulated phosphoinositide 3 kinase (PI3K), AKT and the mammalian target of rapamycin (mTOR) via the mTOR pathway have been reported in metastatic and recurrent cervical cancer patients. Accordingly, a clinical benefit of therapy targeted to these cell signaling pathways has been reported in phase I and II clinical trials (3)(4)(5), consistent with the finding that AKT inhibitors promote cell death in cervical cancer (6).…”
Section: Introductionsupporting
confidence: 70%
“…Upregulated phosphoinositide 3 kinase (PI3K), AKT and the mammalian target of rapamycin (mTOR) via the mTOR pathway have been reported in metastatic and recurrent cervical cancer patients. Accordingly, a clinical benefit of therapy targeted to these cell signaling pathways has been reported in phase I and II clinical trials (3)(4)(5), consistent with the finding that AKT inhibitors promote cell death in cervical cancer (6).…”
Section: Introductionsupporting
confidence: 70%
“…Dysregulation of the PI3K pathway is a common feature of many gynecologic cancers (33) and HPV oncogenic proteins have been shown to activate the P13K pathway (34). In our series, there was a high prevalence of PI3KCA mutations in both HPV-positive and HPV-negative disease, making PI3K pathway inhibition an attractive treatment strategy in the management of patients with VSCC.…”
Section: Targeted Therapeutic Strategies In Vsccmentioning
confidence: 59%
“…PI3K/AKT is a crucial pathway in carcinogenesis and is deregulated in various tumours including cervical cancer 8, 18, 19. Mutation data from many independent studies showed mutations in PIK3CA and PTEN in various proportions in cervical cancer (13%‐23% in PIK3CA, 5%‐8% in PTEN) 20.…”
Section: Discussionmentioning
confidence: 99%